Have any questions? 706-721-6582 or cts@augusta.edu
- SGNTV-003/GOG 3057: A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Clinical Trial
SGNTV-003/GOG 3057: A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
The purpose of this study is to find out what the side effects are, of tisotumab vedotin, and if it works for cervical cancer. The study will also study howeffective tisotumab vedotin is when compared with the standard chemotherapy.
Eligibility Criteria
- Subjects must be 18 years of age or older. Must have recurrent or metastatic cervical cancer with squamous cell, adenocarcinoma, or adenosquamous histology. Subjects must not have clinically significant bleeding issues such as know past or current coagulation defects leading to an increased risk of bleeding, trauma with increased risk of life-threatening bleeding, etc.
RESEARCH. INNOVATION. DISCOVERY.